908 DEVICES INC. Deferred Revenue Recognized
908 DEVICES INC. (MASS) reported Deferred Revenue Recognized of -$4.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-11
- 908 DEVICES INC. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was -$2.50M.
- 908 DEVICES INC. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was -$3.14M.
- 908 DEVICES INC. contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was -$2.57M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month |
|---|---|---|---|
| 2026-06-30 | -$4.68M 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | -$2.50M 10-Q · filed 2026-05-06 | ||
| 2025-09-30 | -$8.35M 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | -$5.95M 10-Q · filed 2026-08-11 | ||
| 2025-03-31 | -$3.14M 10-Q · filed 2026-05-06 | ||
| 2024-09-30 | -$6.35M 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | -$4.55M 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | -$2.57M 10-Q · filed 2025-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |